Drug intelligence / Profile preview

NNC 0070-0002-0453

Development stage: Discontinued
Lead developer: Novo Nordisk
Modality: Peptides, Small Molecules
Administration: Subcutaneous

Overview

NNC 0070-0002-0453 is a novel, long-acting, selective agonist of the melanocortin-4 receptor (MC4R) developed by Novo Nordisk for the treatment of obesity. It was designed to act on the central melanocortin pathway to regulate appetite and energy expenditure. The drug underwent early clinical development but was discontinued after phase 1 due to an unfavorable benefit-risk profile observed in trials with overweight and obese subjects[1][2].

Other names: 2-0453

Targets

MC4R (Melanocortin 4 receptor)

Beyond the preview

Go deeper on NNC 0070-0002-0453.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC 0070-0002-0453.

Explore the full profile